The FDA recognizes the potential opportunities that cannabis or compounds derived from cannabis may offer and recognizes the strong interest in these possibilities. However, the FDA knows that some companies market products containing cannabis and compounds derived from cannabis in a way that violates the Federal Food, Drug and Cosmetic Act (Law FD&C) and that may jeopardize the health and safety of consumers. The agency is committed to protecting public health and, at the same time, taking steps to improve the efficiency of regulatory channels for the legal marketing of appropriate cannabis and cannabis-derived products. The FDA has a number of resources available that address cannabis and cannabis-derived products, such as cannabidiol (CBD), and the agency wants to ensure that consumers and other stakeholders have access to these resources in a centralized location.
To date, the FDA has not approved a request to commercialize cannabis for the treatment of any disease or condition. However, the FDA has approved one cannabis-derived drug and three cannabis-related drugs. These approved products are only available with a prescription from a licensed healthcare provider. The FDA has approved Epidiolex, which contains a purified form of the drug substance CBD, for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged 1 year or older. It has also approved Epidiolex for the treatment of seizures associated with the tuberous sclerosis complex in patients 1 year of age or older.
Marinol and Syndros include the active ingredient dronabinol, a synthetic delta-9-tetrahydrocannabinol (THC) that is considered the psychoactive component of cannabis. Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, which has a chemical structure similar to that of THC and is synthetically derived. The FDA remains concerned about the proliferation of products claiming to contain CBD that are marketed for therapeutic or medical uses, even though they have not been approved by the FDA. Often, these products are sold online and are therefore available across the country. This deceptive marketing of unproven treatments also raises significant public health problems, since patients and other consumers can be influenced not to use approved therapies to treat serious and even fatal diseases. Unlike drugs approved by the FDA, products that have not been reviewed by the FDA as part of the drug approval process have not been evaluated to determine if they work, what the appropriate dose might be if they work, how they might interact with other drugs, or if they have dangerous side effects or other safety problems.
The FDA knows that unapproved cannabis or cannabis-derived products are used to treat a number of medical conditions, such as AIDS wasting syndrome, epilepsy, neuropathic pain, spasticity associated with multiple sclerosis, and nausea induced by cancer and chemotherapy. The FDA relies on applicants and scientific researchers to conduct research. The agency's role is to review data submitted to it in an approval request to ensure that the drug meets legal approval standards. The FDA will continue to facilitate work by companies interested in adequately bringing safe, effective and quality products to market, including scientifically based research on medicinal uses of cannabis. The National Institutes of Health (NIH), particularly the National Cancer Institute (NCI) and National Institute on Drug Abuse (NIDA), can obtain additional information on research into medical use of cannabis. The FDA knows several states have passed laws eliminating state restrictions on medical use of cannabis and its derivatives or are considering doing so.
It is important to conduct medical research on safety and efficacy of cannabis products through appropriate clinical trials. We welcome opportunity to speak with states considering supporting medical research on cannabis and its derivatives so we can provide information on federal and scientific standards. Information on reports of adverse effects on cannabis use is extremely limited; FDA primarily receives adverse event reports for approved products. General information on possible adverse effects of use of cannabis and its components may come from published clinical trials as well as from spontaneously reported adverse events sent to FDA. Additional information is needed on safety and effectiveness of cannabis and its components. Clinical trials with cannabis conducted pursuant to request from IND could collect this important information as part of drug development process. There is an exception to section 201 (ff) (B) if substance was marketed as dietary supplement or conventional food before drug was approved or before new pharmacological research was authorized as appropriate.
However, based on available evidence, FDA has concluded this is not case with THC or CBD. FDA is not aware any evidence could challenge its current findings that products containing THC and CBD are excluded from definition of dietary supplement under section 201 (ff) (B) Act FD&C. Interested parties may submit agency any evidence consider related this issue. Our continuous review information presented so far has not led us change our conclusions. When substance is excluded from definition dietary supplement under section...